뒤로
Prelude Therapeutics Inc(PRLD) 가격
PRLD 주가 차트
PRLD 수입
Prelude Therapeutics Inc
$1.81
-15.81%
$-0.33
종가: Jan 16, 16:00:00 GMT-5
$1.79
-1.1%
$-0.02
애프터마켓: Jan 16, 20:00:00 GMT-5
주요 통계
이전 종가
$2.15
시가
$2.1
일일 범위
$1.78 - $2.1
52주 범위
$0.6101 - $4.22
거래량
1.4M
평균 거래량
1.1M
EPS(TTM)
-0.64
배당수익률
--
시가총액
$112.5M
PRLD란 무엇인가요?
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 131 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.